Asahi Songwon Colors Limited
4,768words
2turns
0analyst exchanges
0executives
Key numbers — 40 extracted
₹33.50 crore
90%
rs,
55%
80%
70%
100%
5 billion
25%
20%
50%
₹82 crore
Guidance — 7 items
Products manufactured
opening
“stake Asahi Songwon Colors will acquire an additional in Atlas Life Sciences Private Limited each year for the next two years based on performance metrics, bringing the company's equity stake to 100% by the end of FY25.”
Products manufactured
opening
“The greenfield project is estimated to cost and will be funded through a combination of internal accrual and debt.”
Products manufactured
opening
“KEY PRODUCERS OF PG IN INDIA The global consumption of PG is 1,430 T growing at 10% CAGR.”
Products manufactured
opening
“We expect all the investments made during the last two years indeed to hold the Company in good stead, going forward.”
Products manufactured
opening
“The current market conditions are very challenging and we expect this cyclical dip to play itself out in a few months.”
Products manufactured
opening
“On the API front, we have recorded a record top line however the margins here too were under pressure and the operating performance will significantly improve going forward.”
Products manufactured
opening
“On a consolidated basis, we expect a strong bounce back in our operating performance coupled with robust revenue growth as our investments in API and Azo's start to pay off.“ A s a h i S o n g w o n C o l o r s L i m i t e d Mr.”
Advertisement
Risks & concerns — 6 flagged
However, once the relationship is established, it becomes difficult for the other player to take the market share.
— Products manufactured
While we witnessed robust growth in our topline, our profitability was under pressure.
— Products manufactured
The decline in realisation coupled with inventory losses has negatively impacted our profitability.
— Products manufactured
While we have indeed outperformed the industry in our blue business and have had a strong start to the 2nd quarter, I would like to mention that the operating environment remains highly uncertain.
— Products manufactured
Barring a few quarters in an uncertain environment, we remain highly optimistic about a strong bounce back in our operating performance.” A s a h i S o n g w o n C o l o r s L i m i t e d Mr.
— Products manufactured
On the API front, we have recorded a record top line however the margins here too were under pressure and the operating performance will significantly improve going forward.
— Products manufactured
Speaking time
2
Advertisement
Opening remarks
Products manufactured
Phthalocyanine Pigments Waste and effluent treatment facilities available • CPC Blue crude • Beta Blue • Alpha Blue Available capacities • 10,200 TPA CPC Blue crude • 3,600 TPA Beta Blue • 600 TPA Alpha Blue Situated on 98,000 sq. mt. plot Available area for further expansion - 25,000 sq. mt. Team strength of 475 people No forced pollution shutdown in the last decade Green cover around factory premises A s a h i S o n g w o n C o l o r s L i m i t e d At Asahi Songwon has entered into a joint venture with UK’s leading colour manufacture Tennants Textiles Colours Limited (TTC) to manufacture red, yellow and orange Azo pigments. 14 WHY AZO PIGMENTS CHINA +1 A STRONG TAILWIND The global organic and specialty pigment market is estimated at $5 billion and Azo is the largest in volume. High demand that is largely met through imports from China Domestic manufacturing will ensure lower cost of production Very few operational player in the segment 25% 20% 55% Azo Pigments Phthalocyanine Pigment
Products manufactured
Azo Pigments Waste and effluent treatment facilities available Situated on 60,000 sq. mt. plot Capacities expandable upto - 10,000 TPA Available capacities • 1,200 TPA Red Pigments • 1,200 TPA Yellow Pigments Team strength of 80 people Phase 2 brownfield capex to begin after reaching 50% capacity utilization levels Available area for further expansion to meet future demand requirements A s a h i S o n g w o n C o l o r s L i m i t e d 17 SALIENT FEATURES FINANCIAL HIGHLIGHTS Incorporated in member team strength Key Products include • Pergabalin • R-Compound • Levosulpiride • Amisulpride • Glicazide • Phenylephrine under research and development, including 6 new molecules and intermediates for existing products Market leader in Established R&D center with team strength of Currently plant running at utilizations FY22 (₹ IN CRORE) Unaudited Figures REVENUE EBITDA PAT A s a h i S o n g w o n C o l o r s L i m i t e d ABOUT ATLAS LIFE SCIENCES PRIVATE LIMITED Atlas is a leading manufacturer
Advertisement